Prelude Capital Management’s Xilio Therapeutics XLO Stock Holding History
Bought
Maintained
Sold
Other funds holding XLO
Prelude Capital Management's XLO Position: Q3 2026 in Review
Prelude Capital Management sold out of Xilio Therapeutics (XLO) in Q3 2026, closing a stake of 11,600 shares — an estimated $111K sold.
Prelude Capital Management first reported a position in XLO in Q1 2024 and held it in 2 quarters. The position peaked at $111K in Q2 2026. 30 funds tracked by Wall St. Rank hold XLO as of Q3 2026.
- Prelude Capital Management reported no remaining Xilio Therapeutics position as of Q3 2026 after selling out during the quarter.
- Prelude Capital Management sold 11,600 Xilio Therapeutics shares in Q3 2026, an estimated $111K.
- Prelude Capital Management first reported a position in Xilio Therapeutics in Q1 2024 and held it in 2 quarters.
- Prelude Capital Management's Xilio Therapeutics position peaked at $111K in Q2 2026.
- 30 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2026.
Based on Prelude Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.